Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

The projected decline in ZYDUSLIFE's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 1.267000
forwardPE 23.271141
debtToEquity 42.242000
earningsGrowth 0.087000
revenueGrowth 0.162000
grossMargins 0.731380
operatingMargins 0.184670
trailingEps 50.070000
forwardEps 46.658650

ZYDUSLIFE's current ratio of 1.267, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as ZYDUSLIFE has enough cash and current assets to handle its immediate liabilities comfortably.
Zydus Lifesciences Limited's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
With forward EPS less than trailing EPS, ZYDUSLIFE is expected to see reduced earnings. This suggests the company may face profitability challenges in the current financial year compared to the previous one.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

ZYDUSLIFE's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


1 separate transactions to buy ZYDUSLIFE were completed, while market price hovered around 951.4000244140625.During the period under consideration, no buy transactions took place.The ongoing selling activity at Zydus Lifesciences Limited's current price levels suggests a potential risk of further declines. If more investors continue to sell, this trend could lead to continued downward pressure on the stock's price.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


The recent buy bias for ZYDUSLIFE from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see ZYDUSLIFE as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.